<DOC>
	<DOC>NCT02032095</DOC>
	<brief_summary>It is intended to examine the safety and efficacy of desensitization therapy by GB-0998 (intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of pre-transplant desensitization. Patients with positive FCXM-T after performing twice double filtration plasmapheresis (DFPP) therapy will receive GB-0998 1g/kg/day for four days.</brief_summary>
	<brief_title>The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Patients with stage 4 or 5 on the CKD classification. Of the patients that wants a livingdonor kidney transplant of ABO blood type compatible, patients with positive FCXMT and negative CDCT to the donor. Patients with positive FCXMT after performing twice DFPP therapy Patients who had taking to continue immunosuppressive drugs or steroids within 4 weeks before obtaining informed consent. Patients who had IVIG therapy, or plasmapheresis therapy within 12 weeks before to informed consent. Patients who had Rituximab within 6 month before to informed consent. Patients who have undergone splenectomy. Patients with severe hepatic disorder or severe heart disorder. Patients with receiving treatment of malignancy. Patients with high risk of thromboembolism. Patients with history of shock or hypersensitivity to GB0998. Patients with hereditary fructose intolerance or IgA deficiency. Patients with pregnant or probably pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>IVIG</keyword>
	<keyword>Renal transplantation</keyword>
	<keyword>desensitization</keyword>
</DOC>